SEARCH

SEARCH BY CITATION

References

  • 1
    Mahoney JF. Long-term results and complications of trans plantation. The kidney. Transpl Proc 1989; 21:14334.
  • 2
    Tufveson G, Geerlings W, Brunner FP et al. Combined report on regular dialysis and transplantation in Europe, XIX, 1988. Nephrol Dial Transpl 1989;4(suppl 4):529.
  • 3
    Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis and transplantation (ed). Kidney Int 1981; 19:62537.
  • 4
    Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:98592.
  • 5
    Editorial. Hyperlipidemia after renal transplantation. Lancet 1988; i:91920.
  • 6
    Harris KPG, Russel GI, Parvin SD, Veitch PS, Walls J. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. Br Med J 1986; 292:16.
  • 7
    Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolaemia. Am J Kidney Dis 1991; 18:3538.
  • 8
    Attman PO, Gustafson A. Lipid and carbohydrate metabolism in uraemia. Europ J Clin Invest 1979; 9:2858.
  • 9
    Keane WF, Kasiske BL. Hyperlipidemia in the nephrotic syndrome. N Engl J Med 1990; 323:6034.
  • 10
    Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; i: 130911.
  • 11
    Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidaemia and progressive renal disease. Kidney Int 1991; 39(suppl 31):S418.
  • 12
    Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318:165766.
  • 13
    Feehally J, Harris KPG, Benneth SE, Walls J. Is chronic renal transplant rejection a non-immunological phenomenon? Lancet 1986; 2:4868.
  • 14
    Fellstrom B, Larsson E, Tufveson G. Strategies in chronic rejection of transplanted organs. A current view on pathogenesis, diagnosis and treatment. Transpl Proc 1989; 21:14359.
  • 15
    Foster MC, Wenham PW, Rowe PA et al. The late results of renal transplantation and the importance of chronic rejection as a cause of graft loss. Ann R Coll Surg Engl 1989; 71:447.
  • 16
    Paul LC, Fellstrom B. Chronic vascular rejection of the heart and the kidney—have rational treatment options emerged? Transplantation 1992; 53:116979.
  • 17
    Foegh ML. Chronic rejection—graft arteriosclerosis. Transpl Proc 1990; 22:11922.
  • 18
    Foegh ML, Khirabadi BS, Nakanishi T, Vargus R, Ramwell P. Estradiol protects against experimental cardiac transplant atherosclerosis. Transpl Proc 1987; 19:902.
  • 19
    Fellström B, Dimeny E, Larsson E, Claesson K, Tufveson G. Rapidly proliferative arteriopathy in cyclosporine-induced permanently surviving rat cardiac allografts simulating chronic vascular rejection. Clin Exp Immunol 1990; 80:28892.
  • 20
    Dimény E, Fellström B, Larsson E, Tufveson G, Lithell H. Lipoprotein abnormalities in renal transplant recipients with chronic vascular rejection. Transpl Proc 1992; 24:366.
  • 21
    Lindholm A, Albrechtsen D, Tufveson G, Karlberg I, Persson NH, Groth CG. A randomized trial of cyclosporine and prednisolone versus cyclosporine, azathioprine and prednisolone in primary cadaveric renal transplantation. Transplantation 1992; 56:62431.
  • 22
    Backman U, Fellström B, Frödin L, Sjöberg O, Tufveson G, Wikstrom B. Successful transplantation in highly sensitized patients. Transpl Proc 1989; 21:7623.
  • 23
    Pollare T, Lithell H, Selinus I, Berne C. Application of proazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31:41520.
  • 24
    Seigler L, Wu WT. Separation of serum high density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. ClinChem 1981; 27:83841.
  • 25
    Wahlberg J, Anderson T, Busch C, Fellström B, Frödin L, Larsson A, Larsson E, Lindgren PG, Tufveson G. The BioptyTM biopsy technique—major advantages in the monitoring of renal transplant recipients. Transpl Proc 1988; 20:41920.
  • 26
    Hanås E, Larsson E, Fellström B et al. Safety aspects and diagnostic findings of serial renal allograft biopsies, obtained by an automatic technique with a midsize needle. Scand J Urol Nephrol 1992; 26:41320.
  • 27
    European Atherosclerosis Society Study Group. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9:571600.
  • 28
    Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine 1987; 66:30916.
  • 29
    Ettinger WH, Bender WL, Goldberg AP, Hazzard WR. Lipoprotein-lipid abnormalities in healthy renal transplant recipients: persistence of low HDL2 cholesterol. Nephron 1987; 47:1221.
  • 30
    Vathsala A, Weinberg RB, Schoenberg L et al. Lipid abnormali ties in renal transplant recipients treated with cyclosporine. Transpl Proc 1989; 21:36703.
  • 31
    Regnström J, Nilsson J, Tornvall P, Landon C, Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; i:11836.
  • 32
    Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differen tiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87:9048.
  • 33
    Fellström B, Larsson E, Claesson K, Tufveson G, Wahlberg J, Klareskog L. Macrophages and T-lymphocytes expressing HLA-D region encoded gene products in rejected renal trans plants. Transpl Proc 1988; 20:3724.
  • 34
    Haller H, Schaper D, Philipp S, Distler A. O-LDL induces surface expression of adhesion molecules ICAM-1 and ELAM on endothelial cells via activation of proteinkinase C. JASN 1992; 3:632.
  • 35
    Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low density lipoprotein that increase its atherogenecity. N Engl J Med 1989; 320:91524.
  • 36
    Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. Functions of vascular wall cells related to development of transplantation associated coronary arteriosclerosis. Transpl Proc 1989; 21:367784.
  • 37
    Corpier CL, Jones PH, Suki WN et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA 1988; 260:23941.
  • 38
    Grundy SM. Management of hyperlipidemia in kidney disease. Kidney Int 1990; 37:84753.
  • 39
    Traindl O, Reading S, Franz M et al. Treatment of hyperlipidemic kidney graft recipients with lovastatin: Effect on LDL-cholesterol and lipoprotein (a). Nephron 1992; 62:3948.
  • 40
    Kupin WL, Venkat KK, Mozes M. Long-term efficacy and safety of lovastatin in the treatment of hypercholesterolaemia in renal transplant recipients. JASN 1992; 3:865.
  • 41
    Wanner C, Hörl WH, Luley CH, Wieland H. Effect of HMGCoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39:75460.